Does the 2017 revision improve the ability of GOLD to predict risk of future moderate and severe exacerbation?

Serhat ErolElif SenYagmur Gizem KilicAhmed YousifOznur Akkoca YildizTuran AcicanSevgi Saryal

Published in: The clinical respiratory journal (2018)

Low FEV1 was an important risk factor for future exacerbations. Downstaging of C1/D1 patients caused heterogeneity in A/B with including patients with low and high risk of future exacerbation. This resulted in a low discriminative power of GOLD 2017 regarding the risk of future exacerbation in groups A and B. This may cause underestimation of disease severity and inadequate treatment especially in A/B patients with low FEV1 .

Keyphrases

chronic obstructive pulmonary disease
current status
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
cystic fibrosis
peritoneal dialysis
single cell
high intensity
early onset
patient reported outcomes
acute respiratory distress syndrome
respiratory failure